FDA grants bioMérieux emergency authorization for one-hour Ebola Dx

BioFire Diagnostics, a subsidiary of French diagnostics outfit bioMérieux, was granted emergency authorization from the FDA for two of its Ebola tests. The company's FilmArray BioThreat-E diagnostic can detect the disease in a blood or urine sample in one hour, beating out current tests which take one to two days to deliver results. The test also forgoes the need for specialized lab processing, as it runs on BioFire lab equipment available in more than 300 U.S. hospitals, Reuters reports. Story | More

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.